ARTICLE | Emerging Company Profile
Cardior: targeting microRNAs to treat heart failure
Emerging Company Profile: Cardior is betting on RNA therapies that aim to help dysfunctional hearts pump more efficiently.
December 31, 2020 9:26 PM UTC
Updated on Jan 4, 2021 at 2:05 PM UTC
Cardior plans to build on early clinical data for its antisense oligonucleotide in heart failure patients by moving the RNA therapy into niche indications where it believes the product can help dysfunctional hearts pump more efficiently.
Cardior Pharmaceuticals GmbH spun out of Hannover Medical School in 2016 to develop non-coding RNA-based therapeutics and diagnostics for cardiovascular diseases. Its lead candidate, CDR132L, is a locked nucleic acid (LNA) antisense oligonucleotide inhibitor of miR-132 to treat heart failure...